Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients

Molecular Biology Reports

Volumn 39, Issue 1, 2012, Pages 351-357

  Ning, Su ^a,b   Bin, Chen ^a,c   Na, Huang ^a   Peng, Shen ^a   Yi, Ding ^a   Ye, Xiang Hua ^a   Zeng, Fang Yin ^a   Zheng, Da Yong ^a   Luo, Rong Cheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU CHEST HOSPITAL   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Glypican 3; Hepatocellular carcinoma; Metastasis; Prognosis; Recurrence

Indexed keywords

GLYPICAN 3;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PATHOLOGY; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION;

CARCINOMA, HEPATOCELLULAR; GENETIC MARKERS; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; SURVIVAL ANALYSIS;

EID: 84855190247     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0745-y     Document Type: Article

References (30)

1. R Mazzanti L Gramantieri L Bolondi 2008 Hepatocellular carcinoma: epidemiology and clinical aspects Mol Aspects Med 29 130 140 18061252 10.1016/j.mam.2007.09.008 (Pubitemid 351312220)
2. MB Thomas AX Zhu 2005 Hepatocellular carcinoma: the need for progress J Clin Oncol 23 2892 2899 15860847 10.1200/JCO.2005.03.196 (Pubitemid 46224106)
3. KK Ng CM Lo CL Liu RT Poon SC Chan ST Fan 2008 Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant Arch Surg 143 68 74 18209155 10.1001/archsurg.2007. 15 discussion (Pubitemid 351159293)
4. Y Kim do YH Paik SH Ahn YJ Youn JW Choi JK Kim KS Lee CY Chon KH Han 2007 PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection Oncology 72 52 57 18087182 10.1159/000111707 (Pubitemid 350256665)
5. J Filmus 2002 The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans Glycoconj J 19 319 323 12975611 10.1023/A:1025312819804 1:CAS:528:DC%2BD3sXmsFWitL8%3D (Pubitemid 37174561)
6. HC Hsu W Cheng PL Lai 1997 Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution Cancer Res 57 5179 5184 9371521 1:CAS:528:DyaK2sXnsV2kur8%3D (Pubitemid 27498138)
7. YK Sung SY Hwang MK Park MK Park M Farooq IS Han HI Bae JC Kim M Kim 2003 Glypican-3 is overexpressed in human hepatocellular carcinoma Cancer Sci 94 259 262 12824919 10.1111/j.1349-7006.2003.tb01430.x 1:CAS:528:DC%2BD3sXktVCqsL4%3D (Pubitemid 36575892)
8. T Nakatsura Y Yoshihiro S Senju M Monji H Komori Y Motomura S Hosaka T Beppu T Ishiko H Kamohara H Ashihara T Katagiri Y Furukawa S Fujiyama M Ogawa Y Nakamura Y Nishimura 2003 Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker Biochem Biophys Res Commun 306 16 25 12788060 10.1016/S0006-291X(03)00908-2 1:CAS:528:DC%2BD3sXkt1GhsL0%3D (Pubitemid 36629398)
9. M Capurro IR Wanless M Sherman G Deboer W Shi E Miyoshi J Filmus 2003 Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 89 97 12851874 10.1016/S0016-5085(03)00689-9 1:CAS:528:DC%2BD3sXmtVWqtbk%3D (Pubitemid 36799110)
10. Ding Yi Chen Bin S Wang L Zhao J Chen Y Ding L Chen R Luo 2008 Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients Int J Cancer 124 653 658
11. LZ Debra G Anita L Chunyan MC Pauline Y Guang-Yu JY Ximing 2008 Expression of glypican3 in hepatoblastoma: an immunohistochemical study of 65 cases Hum Pathol 39 224 230 10.1016/j.humpath.2007.06.006
12. G Pilia RM Hughes-Benzie A MacKenzie P Baybayan EY Chen R Huber G Neri A Cao A Forabosco D Schlessinger 1996 Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome Nat Genet 12 241 247 8589713 10.1038/ng0396-241 1:CAS:528:DyaK28XhvVSgtL4%3D (Pubitemid 26080081)
13. DF Cano-Gauci HH Song H Yang C McKerlie B Choo W Shi R Pullano TD Piscione S Grisaru S Soon L Sedlackova AK Tanswell TW Mak H Yeger GA Lockwood ND Rosenblum J Filmus 1999 Glypican-3 deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome J Cell Biol 146 255 264 10402475 1:CAS:528:DyaK1MXksFCjsL8%3D (Pubitemid 29349979)
14. DG Alfonso K Mitsunori S Wen S Howard RT Joseph ZP Linda F Jorge 1998 OCI 5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell-specific manner J Cell Biol 141 1407 1414 10.1083/jcb.141.6.1407 (Pubitemid 28289915)
15. MG Peters E Farias L Colombo J Filmus L Puricelli DK Bal E Joffe 2003 Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model Breast Cancer Res Treat 80 221 232 12908826 10.1023/A:1024549729256 1:CAS:528:DC%2BD3sXltVWiu7g%3D (Pubitemid 36886511)
16. J Filmus M Capurro J Rast 2008 Glypicans Genome Biol 9 224 18505598 10.1186/gb-2008-9-5-224
17. MI Capurro YY Xiang C Lobe J Filmus 2005 Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling Cancer Res 65 6245 6254 16024626 10.1158/0008-5472.CAN-04-4244 1:CAS:528:DC%2BD2MXmt1egs7g%3D (Pubitemid 40994410)
18. HH Song W Shi YY Xiang J Filmus 2005 The loss of glypican-3 induces alterations in Wnt signaling J Biol Chem 280 2116 2125 15537637 10.1074/jbc.M410090200 1:CAS:528:DC%2BD2MXksVWgtg%3D%3D
19. I Stigliano L Puricelli J Filmus MC Sogayar E Bal MG Peters 2009 Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation Breast Cancer Res Treat 114 251 262 18404367 10.1007/s10549-008-0009-2 1:CAS:528:DC%2BD1MXhsFWnurk%3D
20. Y Torisu A Watanabe A Nonaka Y Midorikawa M Makuuchi T Shimamura H Sugimura A Niida T Akiyama H Iwanari T Kodama M Zeniya H Aburatani 2008 Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF Cancer Sci 99 1139 1146 18429952 10.1111/j.1349-7006.2008.00814.x 1:CAS:528:DC%2BD1cXnsVOrs7Y%3D (Pubitemid 351676625)
21. Z-W Zhu H Friess L Wang M Abou-Shady A Zimmermann AD Lander M Korc J Kleeff MW Büchler 2001 Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 4 558 564 11247902 10.1136/gut.48.4.558 1:CAS:528:DC%2BD3MXislyhurc%3D (Pubitemid 32234802)
22. H Shirakawa H Suzuki M Shimomura M Kojima N Gotohda S Takahashi T Nakagohri M Konishi N Kobayashi T Kinoshita T Nakatsura 2009 Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma Cancer Sci 100 8 1403 1407 19496787 10.1111/j.1349-7006.2009.01206.x 1:CAS:528:DC%2BD1MXhtVWnsLrJ
23. MH Kwack BY Choi YK Sung 2006 Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells Histol Histopatho Mol Cells 21 224 228 1:CAS:528:DC%2BD28Xlt1Wjsrc%3D
24. L Zhou JA Rui SB Wang SG Chen Q Qu 2008 LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy J Surg Res 34 1 7
25. Y Hippo K Watanabe A Watanabe Y Midorikawa S Yamamoto S Ihara S Tokita H Iwanari Y Ito K Nakano J Nezu H Tsunoda T Yoshino I Ohizumi M Tsuchiya S Ohnishi M Makuuchi T Hamakubo T Kodama H Aburatani 2004 Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage of hepatocellular carcinoma Cancer Res 64 2418 2423 15059894 10.1158/0008-5472.CAN- 03-2191 1:CAS:528:DC%2BD2cXis1yjtLY%3D (Pubitemid 38523895)
26. WC Roberta JW Joh PJ Johnson M Monden TM Pawlik TPP Ronnie 2007 Biology of hepatocellular carcinoma Ann Surg Oncol 15 962 971
27. K Nakano T Orita J Nezu T Yoshino I Ohizumi M Sugimoto K Furugaki Y Kinoshita T Ishiguro T Hamakubo T Kodama H Aburatani H Yamada-Okabe M Tsuchiya 2009 Anti-glypican3 antibodies cause ADCC against human hepatocellular carcinoma cells Biochem Biophys Res Commun 378 279 284 19022220 10.1016/j.bbrc.2008.11. 033 1:CAS:528:DC%2BD1cXhsVOisLrP
28. T Ishiguro M Masamichi Sugimoto Y Kinoshita Y Miyazaki K Nakano H Tsunoda I Sugo I Ohizumi H Aburatani Takao Hamakubo T Kodama M Tsuchiya H Yamada-Okabe 2008 Anti-glypican3 antibody as a potential antitumor agent for human liver cancer Cancer Res 68 9832 9838 19047163 10.1158/0008-5472.CAN-08-1973 1:CAS:528:DC%2BD1cXhsVegtbjF
29. T Nakatsura H Komori T Kubo Y Yoshitake S Senju T Katagiri Y Furukawa M Ogawa Y Nakamura Y Nishimura 2004 Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T cell-mediated tumor rejection without autoimmune reactions in mice Clin Cancer Res 10 8630 8640 15623647 10.1158/1078-0432.CCR- 04-1177 1:CAS:528:DC%2BD2cXhtFGjs7fE (Pubitemid 40053431)
30. H Komori T Nakatsura S Senju Y Yoshitake Y Motomura Y Ikuta D Fukuma K Yokomine M Harao T Beppu M Matsui T Torigoe N Sato H Baba Y Nishimura 2006 Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma Clin Cancer Res 12 2689 2697 16675560 10.1158/1078-0432.CCR-05-2267 1:CAS:528: DC%2BD28Xltlams74%3D